Skip to main content

Table 1 Patients’ clinical data vs polymorphisms distribution

From: A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients

Parameter

CYP2C19*2

P value

CYP2C19*3

P value

CYP2C19*17

P value

GG %

GA %

AA %

GG %

GA %

AA %

CC %

CT %

TT %

Familial antecedents

   

0.8

   

0.1

   

0.3

 (+)

0

100

0

 

0

0

100

 

50

50

0

 

 (−)

7.1

82.1

10.8

 

3.9

76.5

19.6

 

15.4

63.1

21.5

 

Personal antecedents

   

0.1

   

NC

   

0.002**

 (+)

16.7

72.2

11.1

 

4.5

68.2

27.3

 

3.6

57.1

39.3

 

 (−)

2.5

87.5

10

 

0

0

0

 

26.3

65.8

7.9

 

Blood pressure

   

0.3

   

0.9

   

0.3

 (+)

13

78.3

8.7

 

4

76

40

 

16.7

61.1

22.2

 

 (−)

2.9

85.7

11.4

 

5.7

77.1

17.2

 

20.8

70.8

8.3

 

Smoking

   

0.8

   

0.2

   

0.8

 (+)

8.7

82.6

8.7

 

8.7

82.6

8.7

 

16.1

64.5

19.4

 

 (−)

5.7

82.9

11.4

 

2.7

73

24.3

 

12.9

61.3

25.8

 

Diabetes

   

0.1

   

0.4

   

0.1

 (+)

14.3

71.4

14.3

 

8

80

12

 

16.1

58.1

25.8

 

 (−)

2.7

89.2

8.1

 

2.9

74.3

22.8

 

11.5

80.8

7.7

 

Dyslipidemia

   

0.5

   

0.5

   

0.1

 (+)

25

75

0

 

11.1

66.7

22.2

 

14.2

42.9

42.9

 

 (−)

11.1

77.8

11.1

 

0

77.8

22.2

 

10

80

10

 
  1. NC none calculated
  2. * Statistically significant (Chi square test)